Skip to content
Triangle logo TriangleGet started
← Full study record

NCT05074940 · OUTCOME

Number of Participants With a Genetic Mutation

Amivantamab in Adenoid Cystic Carcinoma · Source last updated 2026-05-08

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
COUNT_OF_PARTICIPANTS
Unit
Participants
Interval / dispersion
Not reported
Time frame
2 years

What was measured

To determine the molecular signatures of response and resistance to amivantamab via molecular signatures of response and resistance- measured by comprehensive analysis of Transcriptome Sequencing

Analysis population: Of the available data, the number of subjects with a genetic mutation were reported.

Groups in this outcome

Amivantamab

Amivantamab weekly for the first cycle and biweekly thereafter. Amivantamab: Patients will receive amivantamab at 1050mg weekly for the first cycle and biweekly thereafter (1400mg for patients ≥80kg).

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Amivantamab20

Reported measurements

Source class 1
Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Amivantamab14Not reportedNot reportedNot reportedNot reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        value
        14
denoms
  1. counts
    1. group Id
      OG000
      value
      20
    units
    Participants
description
To determine the molecular signatures of response and resistance to amivantamab via molecular signatures of response and resistance- measured by comprehensive analysis of Transcriptome Sequencing
groups
  1. description
    Amivantamab weekly for the first cycle and biweekly thereafter. Amivantamab: Patients will receive amivantamab at 1050mg weekly for the first cycle and biweekly thereafter (1400mg for patients ≥80kg).
    id
    OG000
    title
    Amivantamab
param Type
COUNT_OF_PARTICIPANTS
population Description
Of the available data, the number of subjects with a genetic mutation were reported.
reporting Status
POSTED
time Frame
2 years
title
Number of Participants With a Genetic Mutation
type
OTHER_PRE_SPECIFIED
unit Of Measure
Participants

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice